Improving Work Outcome in People With Recent-onset Schizophrenia
NCT ID: NCT00203788
Last Updated: 2013-07-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
87 participants
INTERVENTIONAL
1999-05-31
2006-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Psychosocial Therapy and Risperidone Treatment in Work Performance in Recent-Onset Schizophrenia
NCT00333177
Effects of Cariprazine on Cardiac Repolarization in Patients With Schizophrenia
NCT01376076
Aripiprazole in the Treatment of Patients With Schizophrenia and Symptoms of Obsessive Compulsive Disorder (OCD)
NCT00374348
Study Comparing Patients Taking Olanzapine and Patients Taking Aripiprazole on Learning of Vocational Skills
NCT00223418
Effects of Risperdal Consta on Ability to Benefit From Social Skills Training in Schizophrenia
NCT00148083
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The Developmental Processes in Schizophrenic Disorders project involves an ongoing series of longitudinal follow-through studies of individuals with a recent onset of schizophrenia. The current protocol focuses particularly on processes affecting work outcome in this initial period after onset of schizophrenia, drawing on findings that link cognitive deficits in schizophrenia to functional outcome. The protocol is determining the effects on work outcome of a rehabilitative intervention designed to enhance search for appropriate work or schooling and to increase ability to maintain work or school activities more successfully. All entering patients are placed on a common antipsychotic medication, oral risperidone, and are provided clinical treatment by a psychiatrist and a case manager. Participating patients are randomly assigned to a combination of Individual Placement and Support (IPS) and group training with the Workplace Fundamentals Module or to a Brokered Vocational Rehabilitation Model.
The protocol is examining the predictors of level of work functioning attained in the context of the work-focused intervention and maintenance on risperidone. Potential neurocognitive and environmental predictors of work and social functioning and clinical course are being examined. Aspects of early perceptual processing, allocation of attention, working memory, secondary verbal memory, and conceptual flexibility that are implicated as influences on functional outcome are assessed, as are potential stresses and supportive influences in the environment.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Individual Placement and Support Plus Workplace Fundamentals Module
Individual Placement and Support
Supported education/employment
Workplace Fundamentals Module
Group skills training on job/school topics
Oral risperidone
Risperidone, starting target dosage was 6 mg, adjusted to level judged optimal by treating psychiatrist
2
Brokered Vocational Rehabilitation
Brokered Vocational Rehabilitation
Vocational rehabilitation through traditional separate state-funded agency
Oral risperidone
Risperidone, starting target dosage was 6 mg, adjusted to level judged optimal by treating psychiatrist
Skills training group
Group social skills training that did not focus primarily on work situations
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Individual Placement and Support
Supported education/employment
Workplace Fundamentals Module
Group skills training on job/school topics
Brokered Vocational Rehabilitation
Vocational rehabilitation through traditional separate state-funded agency
Oral risperidone
Risperidone, starting target dosage was 6 mg, adjusted to level judged optimal by treating psychiatrist
Skills training group
Group social skills training that did not focus primarily on work situations
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* RDC schizophrenia or schizoaffective disorder, mainly schizophrenic subtype
* Residence within commuting distance of UCLA
* Interest in trying to resume work or school
* Speaks English
Exclusion Criteria
* Significant and habitual drug abuse or alcoholism within 6 months of psychotic episode or evidence that substance abuse will be a prominent factor in course of illness
* Mental retardation
* Treatment with risperidone is contraindicated
18 Years
45 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Mental Health (NIMH)
NIH
University of California, Los Angeles
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Keith Nuechterlein, Ph.D.
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Keith H Nuechterlein, PhD
Role: PRINCIPAL_INVESTIGATOR
University of California, Los Angeles, Department of Psychiatry and Biobehavioral Sciences
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UCLA Neuropsychiatric Institute
Los Angeles, California, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Nuechterlein KH, Subotnik KL, Ventura J, Gitlin MF, Green MF, Wallace CJ, Becker DR, Liberman RP, Drake RE, Mintz J. Advances in improving and predicting work outcome in recent-onset schizophrenia. Schizophrenia Bulletin 31(2): 530, 2005.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.